Case filing & court posture: Molecular Templates, Inc. and its affiliate filed chapter 11 on April 20, 2025 in the District of Delaware (Case No. 25-10739). Dkt. 1 The Debtors are clinical-stage biopharmaceutical companies that developed engineered toxin bodies (ETBs) for cancer treatment. Judge Brendan L. Shannon presides.
Liquidity & DIP financing: The Debtors obtained a $12 million DIP facility from K2 HealthVentures, consisting of $3 million in new money and a $9 million roll-up of prepetition secured debt, bearing 13.5% PIK interest. Dkt. 14 The Court entered an interim order on April 28, 2025 Dkt. 56 and a final order on May 23, 2025. Dkt. 113 The filing was precipitated by the June 2024 termination of the Debtors' collaboration with Bristol Myers Squibb and inability to raise capital in 2023-2024. Dkt. 15
Restructuring outcome: The Debtors pursued a prepackaged plan-based reorganization. The Court confirmed the Revised Combined Disclosure Statement and Joint Chapter 11 Plan on July 7, 2025. Dkt. 186 K2 HealthVentures received 100% of new equity in satisfaction of $15 million of prepetition secured claims.
Plan effective date & post-confirmation: The Plan became effective on July 17, 2025. Dkt. 194 A liquidating trust was established to pursue avoidance actions and wind down the estates. General unsecured creditors are projected to receive 1-5% recovery.
Current status: The case remains open in post-confirmation administration. The Debtors and liquidating trust continue to file quarterly post-confirmation reports. Dkt. 259